Beyhan Cengiz

Dr. Beyhan Cengiz


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Transplantation Proceedings
Verified
Journal Article
Closed access
DDD. Dusmez
D. Dusmez
BCBeyhan Cengiz
Beyhan Cengiz
OYO. Yumrutas
O. Yumrutas
TDT. Demir
T. Demir
SOS. Oztuzcu
S. Oztuzcu
CBC. Bagcı
C. Bagcı

18 October 2021 in Mikrobiyoloji Bulteni
Verified
Journal Article
Closed access
ŞAŞebnem Şenol Akar
Şebnem Şenol Akar
SASinem Akçalı
Sinem Akçalı
YÖYunus Özkaya
Yunus Özkaya
FGFatma Merve Gezginci
Fatma Merve Gezginci
BCBeyhan Cengiz
Beyhan Cengiz
EEErhan Eser
Erhan Eser
In this study, it was aimed to prospectively evaluate the efficacy, side effects and seroconversion data of inactive severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), CoronaVac (R) (Sinovac, China) vaccine in healthcare workers. A total of 1053 healthcare workers who were initially seronegative (COV2T (R) SARS-CoV-2 Total Siemens, USA) and vaccinated with inactivated SARS-CoV-2 were included in the study. Quantitative IgG antibodies (ADVIA Centaur (R) SARS-CoV-2 IgG, Siemens, USA) were investigated 28 days after the first vaccine (n=939) and the second vaccine (n=771). In addition, neutralizing antibodies were evaluated via "enzyme linked immunosorbent assay (ELISA)" test (ACE2-RBD Neutralization Assay, Dia-Pro, Italy) 28 days after the first vaccine. Antibody response of the vaccine was evaluated statistically by univariate (Chi-square, Fisher's exact test, Student's t test, Mann-Whitney U, one-way ANOVA and Kruskall Wallis ANOVA tests) analysis and linear regression models. The consistency between quantitative IgG test and neutralizing antibody test was also evaluated in blood samples taken 28 days after second vaccination. Statistical analysis was determined in logarithmically transformed data with statistical analysis with SPSS 23.0 and Stata, and type 1 error level was accepted as 0.05. At least one side effect was reported by 31.3% and 26.8% of the participants after the first and second vaccine, respectively. The most frequent side effect was pain at the injection site with a frequency of 20.4% vs 21.7%. The frequency of applying to a health center due to side effects was 1.0% after the first vaccine and 0.8% after the second vaccine. The percentage of those who produced sufficient quantitative IgG was found as 25.3% (95% CI=22.5-28.1) 28 days after the first vaccine and 97.9% (95% CI=96.9198.93) after the second vaccine. Neutralizing test antibody positivity was found as 97.7% 28 days after the second vaccine. In univariate analysis, the characteristics that significantly increased the quantitative IgG response against inactivated SARS-CoV-2 vaccine were young age (p<0.01), female gender (p< 0.01), being a non-smoker (p<0.001), not having a chronic disease (p=0.019), having had the flu vaccine this year (p=0.012), not being overweight or obese (p=0.020), and having a SARS-CoV2 infection prior to vaccination (p<0.001). In addition, allied health personnel showed significantly lower antibody responses than the other workers (p<0.001). Multiple linear regression models revealed that, female gender, younger age, smoking and previous COVID-19 polymerase chain reaction test positivity significantly affected the quantitative IgG response after vaccination. A 99% agreement was found between the ELISA-based neutralizing antibody test and the quantitative IgG test (Kappa p=0.783) performed on the 28th day after the second vaccination. CoronaVac (R) provides adequate antibody response in 25% of healthcare workers aged 18-64, after 28 days from a single vaccine, and 97% after 28 days from the second vaccine. Antibody response was significantly higher in younger ages, women, non-smokers, and those who had previously encountered SARS-CoV-2. Phase 3 and phase 4 results are needed to show effectiveness of this vaccine in real life.

15 April 2023 in Mikrobiyoloji Bulteni
Verified
Journal Article
Closed access
KÇKübra Çiçek
Kübra Çiçek
YÖYunus Özkaya
Yunus Özkaya
EEErhan Eser
Erhan Eser
ZBZeynep Ceyda Buran
Zeynep Ceyda Buran
ZAZeynep Öykü Öztürk Arıkan
Zeynep Öykü Öztürk Arıkan
FYFerya Karadağ Yalçın
Ferya Karadağ Yalçın
This study was aimed to determine the efficacy of homologous (only CoronaVac or only Pfizer-BioN- Tech) and heterologous (CoronaVac and Pfizer-BioNTech) vaccines during the period when the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron variant was dominant in T0rkiye. Coro- navirus disease-2019 (COVID-2019) infection was confirmed by reverse transcriptase polymerase chain reaction and data on vaccination status against COVID-19 were evaluated during the period of 15 January 2022-1 May 2022 when the SARS-CoV-2 Omicron variant was dominant among 1854 employees fol- lowed in the SARS-CoV-2 Vaccine Cohort of Manisa Celal Bayar University (MCBU) Hospital Health Work-ers. Two separate reference groups were used in the evaluation of vaccine efficacy: those who were never vaccinated and those who received only two doses of CoronaVac. The efficacy of homologous and heter- ologous vaccine models was evaluated with relative risks and attributable risk percentages. MS Excel, SPSS 23.0 and STATA 14.1 package programs were used for statistical analysis. The mean age of the participants was 36.6 +/- 10.0. During the period from January 15th to May 1st 2022, 372 hospital workers were infected with COVID-19. Taking the never vaccinated as the reference group, the most effective model was found to be only the three or more doses of the Pfizer-BioNTech primary vaccination model (85.8%, 95% CI= 40.7-96.6). Models consisting of a single dose of CoronaVac (6.5%, 95% CI=-56.3-44.2) or a single dose of Pfizer-BioNTech (17.7%, 95% CI=-30.2-48.0) booster dose administered after two doses of primary CoronaVac vaccination was not found to be effective against the SARS-CoV-2 Omicron variant. When only two doses of primary CoronaVac vaccination model was taken as the reference group, the model consist-ing of two doses CoronaVac followed by two Pfizer-BioNTech booster doses was effective as 38.4% (95% CI= 15.4-55.3), whereas three doses of Pfizer-BioNTech booster model was effective as 56.4% (95% CI= 33.9-71.3). To conclude, none of the models other than the homologous or heterologous vaccine models containing at least three doses of Pfizer-BioNTech vaccine were effective compared to those unvaccinated. Compared with those who received only two doses of primary Coronavac, models with at least three dos-es of Pfizer-BioNTech reminder doses were more effective against the Omicron variant than other models.

1 August 2021 in Current Molecular Pharmacology
Verified
Journal Article
Closed access
PDF file
BCBeyhan Cengiz
Beyhan Cengiz
MBMehmet Bostancıklıoğlu
Mehmet Bostancıklıoğlu
TDTuncer Demir
Tuncer Demir
HKHayriye Karabulut
Hayriye Karabulut
Recep DokuyucuRecep Dokuyucu
Recep Dokuyucu
MUMustafa Ulaşlı
Mustafa Ulaşlı
Background: Rhinitis medicamentosa, also known as ‘rebound congestion,’ is inflammation of the nasal mucosa caused by the overuse of topical nasal decongestants. Although local decongestants resolve the initial nasal obstruction, the overuse causes rebound obstruction. However, how the overuse of the decongestant causes rhinitis medicamentosa is not known. Objectives: Here, we show the intracellular effects of oxymetazoline, commonly used a local decongestant, on the cell death pathways. We also investigated the antioxidative effects of erdosteine suspension (175 mg/5mL), an antioxidative agent. Methods: Thirty Wistar-albino rats were used to form the rhinitis medicamentosa model. After rhinitis medicamentosa was clinically detected, we removed the whole lungs of animals to perform the molecular analyses of cell death pathways. Results: We found a statistically significant decrease in the expression levels of Atg5 (p=0.021), Atg7 (p=0.013) and Ulk1 (p=0.036) in the oxymetazoline group compared to the control group (p<0.05); however, Caspase 3 expression level was recorded to be significantly increased in the oxymetazoline group, and the expression level of Beclin1 recorded to be substantially increased in the erdosteine group (p=0.001). Conclusion: Based on these grounds, we suggest that vasoconstriction in capillary vessels caused by oxymetazoline could lead to a decrease in the blood supply, which triggers autophagy to ensure cellular homeostasis.

28 February 2025 in Genel Tıp Dergisi
Verified
Journal Article
Open access
PDF file
ASAbdi İbRahim Sönmez
Abdi İbRahim Sönmez
ASAlper Sevinc
Alper Sevinc
İSİbrahim Sarı
İbrahim Sarı
IKİrFan Koruk
İrFan Koruk
MAMusa Aydınlı
Musa Aydınlı
BCBeyhan Cengiz
Beyhan Cengiz
BACKGROUND: Stomach cancer is one of the most common gastrointestinal tract tumors. Its incidence varies according to ethnic group, geographical conditions, dietary habits, economic status, lifestyle and Helicobacter pylori prevalence. Genetic factors play a major role in the pathogenesis of gastric cancer, and the human epidermal growth factor receptor 2 Her2/neu (c-erb B2) gene is one of these factors. METHOD: The objective of this study is to compare any correlation between the amplification level of Her2/neu gene in gastric cancer by real-time polymerase chain reaction (RT-PCR) with Her2 protein overexpression obtained from the same tissue and studied with immunohistochemisry (IHC), and in the event of positivity, to determine its relationshipwith other known prognostic factors such as age, gender, stage, tumor localization and histological type. RESULTS: IHC results indicated Her2 overexpression in 5 (10%) patients and RT-PCRindicated amplification also in 5 (10%) patients. There was no significant correlation between the results determined by the two methods (p> 0.05). Additionally, no statistically significant difference was detected between prognostic factors and gene expressions in tumor tissues (p> 0.05). CONCLUSION: Her2 gene amplification and protein overexpression can potentially contribute to tumor development. Further studies are needed to evaluate false negativity, investigate patient survival in terms of its contribution to prognosis, and corroborate our hypothesis.